Abstract:Abstract Abstract 2941 Current approaches for vaccination and immunotherapy are often capable of eliciting strong T-cell responses against tumor antigens. However, negative regulatory mechanisms within the tumor microenvironment inhibit antitumor T-cell function, leading to evasion from immune attack. One inhibitory mechanism is upregulation of programmed death-ligand 1 (PD-L1/B7H1) expressed on tumor or stromal cells, which binds to programmed death-1 (PD-1) on activated T cells. PD-1 and B7H1 engagement results in diminished antitumor T-cell responses and correlates with poor outcome in murine and human cancers. To cure mice with large tumor burdens by administering tumor vaccines, we hypothesized that it is necessary not only to enhance the immunogenicity of the vaccines, but also to target the suppressive tumor microenvironment and break immune suppression on effector cells. Therefore, we explored combinational treatments in a myeloma setting by using vaccination and anti-B7H1 blocking mAbs to enhance clinical efficacy of cancer vaccines. To establish mouse tumor models for evaluation of tumor-associated B7H1 in the inhibition of T-cell immunity, first, we examined the expression of B7H1 in four murine myeloma cell lines that originated from Balb/c mice. Results showed that all the myeloma cells expressed a negative T-cell costimulatory molecule B7H1, and blocking surface B7H1 by using a specific mAb (M5H1) enabled tumor-specific CTLs from vaccinated mice to be more efficient at lysing the tumor cells. Thus these results suggest that B7H1 on tumor cells and PD-1 on T cells may form a B7H1/PD-1 molecular shield to prevent lysis by T cells and actively inhibit the cytolytic function of tumor-specific CTLs by expressing B7H1. Next, we evaluated the therapeutic efficacy of DKK1-DNA vaccine in mice with established myeloma. In these experiments, DKK1-DNA vaccine plus CpG was used as a standard vaccine. Anti-B7H1 (M5H1) mAb was used to block negative T-cell signaling in mice receiving DKK1-DNA vaccination. Balb/c mice were first inoculated subcutaneously with the myeloma cells (1 million cells per mouse). Ten days after tumor inoculation, mice were immunized with three injections of the vaccines on days 10, 14, and 17 after tumor inoculation. Mice were also injected intraperitoneally with B7H1 (200 μg per mouse per treatment) on days 1, 4, 7, and 10 following the first vaccination. Mice receiving injections of PBS, isotype IgG (200 μg per mouse per treatment), or CpG- (50 μg per mouse per treatment) alone were used as controls. Results show that mice receiving DKK1-DNA vaccine (plus CpG) together with B7H1 induced more robust tumor growth inhibition (P < 0.01, compared with PBS control mice). The survival of DKK1-CpG vaccine- and vaccine plus B7H1 antibody-treated mice were 60% and 80%, respectively. Thus, our data showed that B7H1 blocking mAbs can further enhance the therapeutic efficacy of the vaccine. Finally, we investigated the mechanism of therapeutic efficacy of vaccine enhanced by anti-B7H1 mAbs. Our results showed that the percentages of IL-10-secreting or Foxp3+ Tregs in the spleens and tumors are significantly decreased in mice vaccinated with DKK1 DNA plus CpG in combination with anti-B7H1 antibodies (P < 0.01, compared with mice receiving DKK1 DNA alone or vaccine plus CpG). These results indicate that myeloma cells are able to induce or recruit regulatory T cells, and the beneficial effects of anti-B7H1 mAbs were derived from their ability to reduce the numbers of Tregs in tumor-bearing mice. Taken together, these results support the concept that B7H1/PD-1 forms a molecular shield to prevent destruction by CTLs and implicate new approaches for immunotherapy of human cancers by B7H1 blocking mAbs. Disclosures: No relevant conflicts of interest to declare.

Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

Dendritic Cell Vaccines Are Superior to Idiotype-KLH Protein Vaccines at Priming a Therapeutic, Tumor-Specific Immunity Against Multiple Myeloma.

Efficacy of Intrathecal Delivery of Peptide-Pulsed Type 1 Conventional Dendritic Cell Vaccine for the Treatment of Breast Cancer-Associated Leptomeningeal Disease in Preclinical Models.

Anti-Myeloma Effects Induced by Myeloma Idiotype Pulsed Dendritic Cells in Vitro.

Active Vaccination With Dkk1 Induces Protective And Therapeutic Antitumor Immunity In Multiple Myeloma.

Co-immunizing with PD-L1 Induces CD8+ DCs-mediated Anti-Tumor Immunity in Multiple Myeloma.

CpG or IFN-α Are More Potent Adjuvants Than GM-CSF to Promote Anti-Tumor Immunity Following Idiotype Vaccine in Multiple Myeloma

Active Vaccination with Dickkopf-1 Induces Protective and Therapeutic Antitumor Immunity in Murine Multiple Myeloma.

[Induction of Active Antitumor Immune Response by Myeloma Idiotype Protein-Pulsed Dendritic Cells].

Blockade of B7H1 by Monoclonal Antibodies Enhances Therapeutic Immunity of DKK1 Vaccine in Multiple Myeloma

[Antitumor Immune Responses Induced by Idiotype-Pulsed Dendritic Cells with Cell-Penetrating Peptide Vaccination in Vivo].

Human DKK1 and human HSP70 fusion DNA vaccine induces an effective anti-tumor efficacy in murine multiple myeloma.

Dendritic cell/myeloma hybrid vaccine.

DKK-1 Is a Widely Expressed, Potent Tumor-Associated Antigen in Multiple Myeloma Recognized by Cytotoxic T Lymphocytes.

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in BALB/C mice.

Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal While Th2 Cells Promote Tumor Growth

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Immunization Against Murine Multiple Myeloma with Fusions of Dendritic and Plasmacytoma Cells is Potentiated by Interleukin 12

Id-neoantigen vaccine induces therapeutic CD8+ T cells against multiple myeloma: H chain-loss escapees cause FLC MM

Targeting Dkk1 For The Immunotherapy Of B-Cell Lymphomas